These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 38634132)

  • 21. Baricitinib: From Rheumatoid Arthritis to COVID-19.
    Assadiasl S; Fatahi Y; Mosharmovahed B; Mohebbi B; Nicknam MH
    J Clin Pharmacol; 2021 Oct; 61(10):1274-1285. PubMed ID: 33870531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Janus kinase inhibitors for the treatment of COVID-19.
    Kramer A; Prinz C; Fichtner F; Fischer AL; Thieme V; Grundeis F; Spagl M; Seeber C; Piechotta V; Metzendorf MI; Golinski M; Moerer O; Stephani C; Mikolajewska A; Kluge S; Stegemann M; Laudi S; Skoetz N
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD015209. PubMed ID: 35695334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of drugs used in rheumatology for treating SARS-CoV2 infection.
    Atzeni F; Gerratana E; Giallanza M; La Corte L; Nucera V; Miceli G; Sangari D; Masala IF
    Expert Opin Biol Ther; 2021 Feb; 21(2):219-228. PubMed ID: 32866053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of the IFN-α JAK/STAT Pathway by MERS-CoV and SARS-CoV-1 Proteins in Human Epithelial Cells.
    Zhang Y; Gargan S; Roche FM; Frieman M; Stevenson NJ
    Viruses; 2022 Mar; 14(4):. PubMed ID: 35458397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Baricitinib Ameliorates Experimental Autoimmune Encephalomyelitis by Modulating the Janus Kinase/Signal Transducer and Activator of Transcription Signaling Pathway.
    Dang C; Lu Y; Chen X; Li Q
    Front Immunol; 2021; 12():650708. PubMed ID: 33927721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Machine learning identifies molecular regulators and therapeutics for targeting SARS-CoV2-induced cytokine release.
    Chan M; Vijay S; McNevin J; McElrath MJ; Holland EC; Gujral TS
    Mol Syst Biol; 2021 Sep; 17(9):e10426. PubMed ID: 34486798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kidney injury in COVID-19 patients, drug development and their renal complications: Review study.
    Mohamadi Yarijani Z; Najafi H
    Biomed Pharmacother; 2021 Oct; 142():111966. PubMed ID: 34333286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kidney involvement in COVID-19 and its treatments.
    Han X; Ye Q
    J Med Virol; 2021 Mar; 93(3):1387-1395. PubMed ID: 33150973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Baricitinib counteracts metaflammation, thus protecting against diet-induced metabolic abnormalities in mice.
    Collotta D; Hull W; Mastrocola R; Chiazza F; Cento AS; Murphy C; Verta R; Alves GF; Gaudioso G; Fava F; Yaqoob M; Aragno M; Tuohy K; Thiemermann C; Collino M
    Mol Metab; 2020 Sep; 39():101009. PubMed ID: 32413585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The 11th Trial of a Cardiovascular Clinical Trialist: Coronavirus-2: Part 5.
    Frishman WH
    Cardiol Rev; 2021 May-Jun 01; 29(3):109. PubMed ID: 33758124
    [No Abstract]   [Full Text] [Related]  

  • 31. JAK inhibitors and COVID-19.
    Levy G; Guglielmelli P; Langmuir P; Constantinescu SN
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35459733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secondary infections and long-term outcomes among hospitalized elderly and non-elderly patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and treated with baricitinib: a comparative study from the national centre of Hungary.
    Gáspár Z; Szabó BG; Andrikovics H; Ceglédi A; Rajmon M; Ábrahám A; Várnai Z; Kiss-Dala N; Szlávik J; Sinkó J; Vályi-Nagy I; Lakatos B
    Geroscience; 2024 Jun; 46(3):2863-2877. PubMed ID: 38367195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Network-Based Analysis Reveals the Mechanism Underlying Vitamin D in Suppressing Cytokine Storm and Virus in SARS-CoV-2 Infection.
    Ahmed F
    Front Immunol; 2020; 11():590459. PubMed ID: 33362771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis.
    Chen CX; Wang JJ; Li H; Yuan LT; Gale RP; Liang Y
    Leukemia; 2021 Sep; 35(9):2616-2620. PubMed ID: 33990684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus.
    Lee J; Park Y; Jang SG; Hong SM; Song YS; Kim MJ; Baek S; Park SH; Kwok SK
    Front Immunol; 2021; 12():704526. PubMed ID: 34497607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Compassionate use of ruxolitinib in patients with SARS-Cov-2 infection not on mechanical ventilation: Short-term effects on inflammation and ventilation.
    Mortara A; Mazzetti S; Margonato D; Delfino P; Bersano C; Catagnano F; Lauriola M; Grosso P; Perseghin G; Ippoliti G
    Clin Transl Sci; 2021 May; 14(3):1062-1068. PubMed ID: 33403775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Baricitinib attenuates the proinflammatory phase of COVID-19 driven by lung-infiltrating monocytes.
    Dobosh B; Zandi K; Giraldo DM; Goh SL; Musall K; Aldeco M; LeCher J; Giacalone VD; Yang J; Eddins DJ; Bhasin M; Ghosn E; Sukhatme V; Schinazi RF; Tirouvanziam R
    Cell Rep; 2022 Jun; 39(11):110945. PubMed ID: 35688145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of JAK-STAT signaling in the pathogenic behavior of fibroblast-like synoviocytes in rheumatoid arthritis: Effect of the novel JAK inhibitor peficitinib.
    Emori T; Kasahara M; Sugahara S; Hashimoto M; Ito H; Narumiya S; Higashi Y; Fujii Y
    Eur J Pharmacol; 2020 Sep; 882():173238. PubMed ID: 32561292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of JAK-STAT Signaling by Baricitinib Reduces Interferon-γ-Induced CXCL10 Production in Human Salivary Gland Ductal Cells.
    Aota K; Yamanoi T; Kani K; Ono S; Momota Y; Azuma M
    Inflammation; 2021 Feb; 44(1):206-216. PubMed ID: 32772240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The roles of Eph receptors, neuropilin-1, P2X7, and CD147 in COVID-19-associated neurodegenerative diseases: inflammasome and JaK inhibitors as potential promising therapies.
    Zalpoor H; Akbari A; Samei A; Forghaniesfidvajani R; Kamali M; Afzalnia A; Manshouri S; Heidari F; Pornour M; Khoshmirsafa M; Aazami H; Seif F
    Cell Mol Biol Lett; 2022 Feb; 27(1):10. PubMed ID: 35109786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.